Newsfeeds - Spark Newswire

1 minute read

News

Aprea Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Today, 6:56 AM

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage

APRE

2 minute read

Reported Late Wednesday Feb 22, Aprea Therapeutics Announces Pricing Of $5.5M Underwritten Public Offering Of 1.05M Shares Of Common Stock At A Price Of $5.25/Share

By Happy Mohamed

Today, 6:56 AM

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response

APRE

5 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 6:56 AM

Friday's session saw 75 companies set new 52-week lows.

AATC

6 minute read

Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday

By Lisa Levin

Today, 6:56 AM

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.

3 minute read

Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 6:56 AM

Gainers

AIRS

5 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 6:56 AM

On Friday, 63 stocks hit new 52-week lows.

ACEV

30 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 6:56 AM

During Wednesday's trading, 517 companies set new 52-week lows.

$APE

1 minute read

HC Wainwright & Co. Assumes Aprea Therapeutics at Buy, Announces Price Target of $3

By Benzinga Newsdesk

Today, 6:56 AM

HC Wainwright & Co. analyst Joseph Pantginis assumes Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $3.

APRE

6 minute read

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday

By Lisa Levin

Today, 6:56 AM

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.

AAPL